To ATCC Valued Customers,

ATCC stands ready to support our customers’ needs during the coronavirus pandemic. Our first job is to listen to and observe what our customers need, and meet those needs with quality products and services. While we are not currently experiencing delays due to this pandemic, we expect that we could see them as the situation evolves. If you experience any issues, please contact ATCC Customer Service at sales@atcc.org. For Technical questions please contact tech@atcc.org. Thank you for your understanding, patience and flexibility as ATCC does everything it can to help reduce the impact of the coronavirus pandemic to our valued customers.
X

MCF-7 Tam1 (ATCC® CRL-3435)

Organism: Homo sapiens, human  /  Tissue: mammary gland; breast  /  Disease: ductal carcinoma

Permits and Restrictions

View Permits

Organism Homo sapiens, human
Tissue mammary gland; breast
Product Format frozen
Morphology epithelial-like
Culture Properties adherent
Biosafety Level 1

Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.

Disease ductal carcinoma
Gender female
Storage Conditions liquid nitrogen vapor phase
Images
Comments

Derived from MCF-7 (ATCC HTB-22) cell line, continuously cultured with 1 µM 4-OH-tamoxifen for 8-12 months to obtain a tamoxifen resistant cell line

Complete Growth Medium

The base medium for this cell line is Dulbecco's Minimum Essential Medium (DMEM; ATCC 30-2002). To make the complete medium add the following components to the base medium:

  • 10% Fetal Bovine Serum (FBS; ATCC 30-2020)
  • 10 µg/mL human insulin (Sigma cat# I9278)
  • 1 µM 4-hydroxytamoxifen


Subculturing
Volumes used in this protocol are for 75 cm2 flask; proportionally reduce or increase amount of dissociation medium for culture vessels of other sizes. Corning® T-75 flasks (catalog #430641) are recommended for subculturing this product.
  1. Remove and discard culture medium.
  2. Briefly rinse the cell layer with 0.25% (w/v) Trypsin- 0.53 mM EDTA solution to remove all traces of serum that contains trypsin inhibitor.
  3. Add 2.0 to 3.0 mL of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).
    Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37°C to facilitate dispersal.
  4. Add 6.0 to 8.0 mL of complete growth medium and aspirate cells by gently pipetting.
  5. Add appropriate aliquots of the cell suspension to new culture vessels.
    Cultures can be established between 1.5 x 104 and 5.0 x 104 viable cells/cm2.
  6. Incubate cultures at 37°C.
Interval: Maintain cultures at a cell concentration between 1.0 X 104 and 3.1 X 105 cell/cm2.
Subcultivation Ratio: A subcultivation ratio of 1:3 to 1:8 is recommended
Medium Renewal: 2 to 3 times per week
Cryopreservation Culture medium (without 4-hydroxytamoxifen) + 5% DMSO (ATCC 4-X)
Culture Conditions
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Temperature: 37°C
Cells per Vial Approximately 2.0 to 3.0 x 106 cells
Sterility Tests Bacteria and yeast: No growth
Mycoplasma: No growth
Population Doubling Time 1 to 2 weeks per the depositor
Name of Depositor University of Helsinki
Year of Origin 2011
References

Kangaspeska S, et al. Systematic drug screening reveals specific vulnerabilities and co-resistance patterns in endocrine-resistant breast cancer. BMC Cancer 16:378, 2016 doi: 10.1186/s12885-016-2452-5. PubMed: 27378269

Notice: Necessary PermitsPermits

These permits may be required for shipping this product:

  • Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.
Basic Documentation
Other Documentation
References

Kangaspeska S, et al. Systematic drug screening reveals specific vulnerabilities and co-resistance patterns in endocrine-resistant breast cancer. BMC Cancer 16:378, 2016 doi: 10.1186/s12885-016-2452-5. PubMed: 27378269